Elsevier: Goodman & Snyder: Differential Diagnosis for Physical Therapists Screening for Referral, 5th Edition - Chapter 12 Screening for Immunologic Disease

Chapter 12 Screening for Immunologic Disease

  1. Klippel JH, editor: Primer on the rheumatic diseases, ed 13, Atlanta, 2008, Arthritis Foundation.
  2. Centers for Disease Control and Prevention (CDC): HIV/AIDS & STDs: fact sheet. Available at http://www.cdc.gov/std/hiv/STDFact-STD-HIV.htm. Accessed January 19, 2011.
  3. Centers for Disease Control and Prevention National Prevention Information Network (NPIN): African-Americans. Available at http://www.cdcnpin.org/scripts/population/afram.asp. Accessed January 4, 2011.
  4. West-Ojo T: Expanded HIV testing and trends in diagnoses of HIV infection, 2004-2008. MMWR 59(24):737–741, 2010. Medline abstracts
  5. Jaffe H, Janssen R: Incorporating HIV prevention into the medical care of persons living with HIV. MMWR 52(RR 12):1–24, 2003.
  6. McIntyre J: Preventing mother-to-child transmission of HIV: successes and challenges. BJOG 112(9):1196–1203, 2005. Medline abstracts
  7. Coutsoudis A: Infant feeding dilemmas created by HIV: South African experiences. J Nutr 135(4):956–959, 2005. Medline abstracts
  8. Zou S: Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 50:1495–1504, 2010. Medline abstracts
  9. Stramer SL: Third reported US case of breakthrough HIV transmission from NAT screened blood. Transmission 43(suppl):40A, 2003.
  10. Laffoon B: HIV transmission through transfusion. MMWR 59(41):1335–1339, 2010. Medline abstracts
  11. Workowski KA: Sexually transmitted diseases treatment guidelines, 2010. MMWR 59(RR12):1–110, 2010. Medline abstracts
  12. Qaqish RB, Sims KA: Bone disorders associated with the human immunodeficiency virus: pathogenesis and management. Pharmacotherapy 24(10):1331–1346, 2004. Medline abstracts
  13. Abrescia N, D’Abbraccio M, Figoni M, et al: Hepatotoxicity of antiretroviral drugs. Curr Pharm Des 11(28):3697–3710, 2005. Medline abstracts
  14. Baba M: Advances in antiviral chemotherapy. Uirusu 55(1):69–75, 2005. Medline abstracts
  15. Nunez M: Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 52(3):1143–1155, 2010. Medline abstracts
  16. Malita FM, Karelis AD, Toma E, et al: Effects of different types of exercise on body composition and fat distribution in HIV-infected patients: a brief review. Can J Appl Physiol 30(2):233–245, 2005. Medline abstracts
  17. Sweet DE: Metabolic complications of antiretroviral therapy. Top HIV Med 13(2):70–74, 2005. Medline abstracts
  18. Magkos F: Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy. Metabolism 60(6):749–753, 2011. Epub October 20, 2010. Medline abstracts
  19. Troll JG: Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. Curr Atheroscler Rep 13(1):51–56, 2011. Epub Dec. 23, 2010. Medline abstracts
  20. Carbone A, Gloghini A: AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol 130(5):662–670, 2005. Medline abstracts
  21. Kasamon YL, Ambinder RF: AIDS-related primary central nervous system lymphoma. Hematol Oncol Clin North Am 19(4):665–687, 2005. Medline abstracts
  22. Sherman M: Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25(2):143–154, 2005.
  23. Trends in tuberculosis—United States, 2010. MMWR 60(11): 333–337, 2011.
  24. Deshpande A, Mrinal M, Patnaik M: Nonopportunistic neurologic manifestations of the human immunodeficiency virus: an Indian study, eJIAS. Medscape Gen Med 7(3):1–2, 2005. Available at http://www.medscape.com/viewarticle/511865. Accessed online January 26, 2010.
  25. Cade W, Peralta L, Keyser R: Aerobic exercise dysfunction in HIV: A potential link to physical disability. Phys Ther 84(7): 655–664, 2004. Medline abstracts
  26. Frey Law LA: Spreading of pain: women vs. men. J Pain 9(4 suppl 2):P9 Abs #134, 2008.
  27. Williams DA, Clauw DJ: Understanding fibromyalgia: lessons from the broader pain research community. J Pain 10(8):777–791, 2009. Medline abstracts
  28. Lowe JC, Yellin J: Inadequate thyroid hormone regulation as the main mechanism of fibromyalgia: a review of the evidence. Thyroid Science 3(6):R1–14, 2008.
  29. Khanis A: Diagnosing fibromyalgia: moving away from tender points. J Musculoskel Med 27(4):155–162, 2010.
  30. Wolfe F: Stop using the American College of Rheumatology criteria in the clinic. J Rheumatol 30(8):1671–1672, 2003. Medline abstracts
  31. Wolfe F: Pain extent and diagnosis: development and validation of the regional pain scale in 12,799 patients with rheumatic disease. J Rheumatol 30:369–378, 2003. Medline abstracts
  32. Wolfe F, Rasker JJ: The Symptom Intensity Scale, fibromyalgia, and the meaning of fibromyalgia-like symptoms. J Rheumatol 22:2291–2299, 2006.
  33. Wolfe F: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 62:600–610, 2010.
  34. Bernstein C, Marcus D: Fibromyalgia: Current concepts in diagnosis, pathogenesis, and treatment. Pain Medicine News 6(9):8–19, December 2008.
  35. Lowe JR, Yellin JG: The metabolic treatment of fibromyalgia, Utica, KY, 2000, McDowell Publishing Company. (Available from McDowell Publishing Company; phone: (603) 769–9590; online at http://www.McDowellPublishing.com).
  36. American Association for Chronic Fatigue Syndrome: CFS Conference Highlights: The merging of two syndromes. Fibromyalgia Network 61:4–70, 2003.
  37. Weissbecker I: Childhood trauma and diurnal cortisol disruption in fibromyalgia syndrome. Psychoneuroendocrinology 31(3):312–327, 2006. Medline abstracts
  38. Bradley LA: Pathophysiologic mechanisms of fibromyalgia and its related disorders. J Clin Psychiatr 69(suppl 2):6–13, 2008.
  39. Wallace DJ: Hypothesis: bipolar illness with complaints of chronic musculoskeletal pain is a form of pseudofibromyalgia. Semin Arthritis Rheum 37:256–259, 2008. Medline abstracts
  40. Leventhal L, Bouali H: Fibromyalgia: 20 clinical pearls. J Musculoskel Med 20(2):59–65, 2003.
  41. Clauw D: Fibromyalgia: Correcting the misconceptions. J Musculoskel Med 20(10):467–472, 2003.
  42. Weingarten TN: Impact of tobacco use in patients presenting to a multidisciplinary outpatient treatment program for fibromyalgia. Clin J Pain 25(1):39–43, 2009. Medline abstracts
  43. Hulme J: Fibromyalgia: a handbook for self-care and treatment, ed 3, Missoula, MT, 2001, Phoenix. www.phoenixpub.com; 1-800-549-8371.
  44. Koch A: Targeting cytokines and growth factors in RA. J Musculoskel Med 22(3):130–136, 2005.
  45. Yavari N: What role do occupational exposures play in RA? J Musculoskel Med 25(3):130–136, 2008.
  46. Andreoli TE, Benjamin I, Griggs, RC, et al: Andreoli and Carpenter’s Cecil essentials of medicine, ed 8, Philadelphia, 2010, WB Saunders.
  47. Anderson D: Development of an instrument to measure pain in rheumatoid arthritis: Rheumatoid Arthritis Pain Scale (RAPS). Arthritis Care Res 45:317–323, 2001.
  48. Freeston J, Keenan AM, Emery P: Spotting the early warning signs of aggressive RA. J Musculoskel Med 25(3):110–115, 2008.
  49. Bykerk V, Keystone E: RA in primary care: 20 clinical pearls. J Musculoskel Med 21(3):133–146, 2004.
  50. Yazici Y, Erkan D, Paget S: Inflammatory musculoskeletal diseases in the elderly, Part I. J Musculoskel Med 19(7):265–276, 2002.
  51. Moorthy L, Onel K: Juvenile idiopathic arthritis: making the diagnosis. J Musculoskel Med 21(11):581–588, 2004.
  52. Clinical Update: advances in rheumatology: new approaches to early diagnosis and treatment. J Musculoskel Med 21(10): 509–560, 2004.
  53. Olson NY, Lindsley CB: Advances in pediatric rheumatology paving the way to better care. J Musculoskel Med 25:505–512, 2008.
  54. Flendrie M, Vissers WH, Creemers MC, et al: Dermatological conditions during TNR-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 7(3):R666–R676, 2005. Medline abstracts
  55. Taylor M, Furst D: Biologic response modifiers: addressing the safety concerns. J Musculoskel Med 22(5):223–239, 2005.
  56. Labbe P, Hardouin P: Epidemiology and optimal management of polymyalgia rheumatica. Drugs Aging 13(2):109–118, 1998. Medline abstracts
  57. Spiera R, Spiera H: Inflammatory diseases in older adults: polymyalgia rheumatica. Geriatrics 59(11):39–43, 2004. Medline abstracts
  58. Gonzalez-Gay MA: Giant cell arteritis: epidemiology, diagnosis, and management. Curr Rheumatol Rep 12(6):436–442, 2010. Medline abstracts
  59. Reiter S: Giant cell arteritis misdiagnosed as temporomandibular disorder: a case report and review of the literature. J Orofac Pain 23(4):360–365, 2009. Medline abstracts
  60. Salvarani C, Cantini F, Bioardi L, et al: Polymyalgia rheumatica. Best Pract Res Clin Rheumatol 18(5):705–722, 2004. Medline abstracts
  61. Hernandez-Rodriguez J: Medical management of polymyalgia rheumatica. Expert Opin Pharmacother 11(7):1077–1087, 2010. Medline abstracts
  62. Grau RH: Cutaneous cues to diagnosis of lupus. J Musculoskel Med 24(6):247–263, 2007.
  63. Lupus Foundation of America (LFA): Understanding lupus. (One of five patient education booklets available at www.lupus.org.) Accessed March 3, 2011.
  64. Formica MK, Palmer JR, Rosenberg L, et al: Smoking, alcohol consumption, and risk of systemic lupus erythematosus in the Black Women’s Health Study. J Rheumatol 30:1222–1226, 2003. Medline abstracts
  65. Petri M: Systemic lupus erythematosus: new management strategies. J Musculoskel Med 22(3):108–116, 2005.
  66. Sayarlioglu M: Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int Epub Aug 15, 2010.
  67. Bertsias GK: EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations. Report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69(12):2074–2082, 2010. Medline abstracts
  68. Muscal E, Brey RL: Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin 28(1):61–73, 2010. Medline abstracts
  69. Zulian F, Vallongo C, Woo P, et al: Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 52(9): 2873–2881, 2005. Medline abstracts
  70. Steen VD: Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg 17(1):48–54, 1998. Medline abstracts
  71. Steen VD: Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35(1):35–42, 2005. Medline abstracts
  72. Steen VD, Syzd A, Johnson JP, et al: Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 32(4):649–655, 2005. Medline abstracts
  73. Moxley G: Scleroderma and related diseases, WebMD Scientific American® Medicine. Posted 03/22/2004. Available at: www.medscape.com/viewarticle/472036. Accessed November 28, 2005.
  74. Highland KB, Silver RM: New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol 17(6):737–745, 2005. Medline abstracts
  75. Hassoun M: Lung involvement in systemic sclerosis. Presse Med 40(1 Pt 2):e3–e17, 2010. Medline abstracts
  76. Haroon N, Inman RD: Ankylosing spondylitis: new criteria, new treatments. Bull NYU Hosp Joint Dis 68(3):171–174, 2010.
  77. Zeidler H, Amor B: The Assessment in Spondyloarthritis International Society (ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress. Ann Rheum Dis 70:1–3, 2011. Medline abstracts
  78. Gomez KS, Raza K, Jones SD, et al: Juvenile onset ankylosing spondylitis: more girls than we thought? J Rheumatol 24(4):735–737, 1997. Medline abstracts
  79. Ostensen M, Ostensen H: Ankylosing spondylitis: the female aspect. J Rheumatol 25(1):120–124, 1998. Medline abstracts
  80. Toussirot E: Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis, and pharmacological therapies. Drugs Aging 27(7): 523–531, 2010. Medline abstracts
  81. Levine DS, Forbat SM, Saifuddin A: MRI of the axial skeletal manifestations of ankylosing spondylitis. Clin Radiol 59(5): 400–413, 2004. Medline abstracts
  82. Lewis R, Creamer P: Ankylosing spondylitis: early diagnosis and management. J Musculoskel Med 20(4):184–198, 2003.
  83. Hitchon P, From A, Brenton M, et al: Fractures of the thoracolumbar spine complicating ankylosing spondylitis. J Neurosurg (Spine 2) 97:218–222, 2002. Medline abstracts
  84. Tullous MW, Skerhut HEI, Story JL, et al: Cauda equina syndrome of long-standing ankylosing spondylitis: case report and review of the literature. J Neurosurg 73:441–447, 1990. Medline abstracts
  85. Ahn NU, Ahn UM, Nallamshetty L, et al: Cauda equina syndrome in ankylosing spondylitis (the CES-AS syndrome): meta-analysis of outcomes after medical and surgical treatments. J Spinal Disord 14(5):427–433, 2001. Medline abstracts
  86. Korendowych E, McHugh N: Genetic factors in psoriatic arthritis. Curr Rheumatol Rep 7(4):306–312, 2005. Medline abstracts
  87. Leong TT, Faron U, Veale DJ: Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis. Curr Rheumatol Rep 7(4):325–329, 2005. Medline abstracts
  88. Qureshi AA, Husni ME, Mody E: Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg 24(1):46–51, 2005. Medline abstracts
  89. Milewski MD: Lyme arthritis in children presenting with joint effusions. J Bone Joint Surg 93A(2):252–260, 2011.
  90. Smith BG: Lyme disease and the orthopaedic implications of Lyme arthritis. J Am Acad Orthop Surg 19(2):91–100, 2011. Medline abstracts
  91. Kalish R, Biggee B: Lyme disease: 20 clinical pearls. J Musculoskel Med 20(6):271–285, 2003.
  92. Making sense of multiple sclerosis. Harvard Women’s Health Watch 12(11):4–6, 2005.
  93. Munger KL, Zhang SM, O’Reilly E, et al: Vitamin D intake and incidence of multiple sclerosis. Neurology 62(1):60–65, 2004. Medline abstracts
  94. Galea I, Newman TA, Gidron Y: Stress and exacerbations in multiple sclerosis. BMJ 328(7434):287, 2004.
  95. Haslam C: Managing bladder symptoms in people with multiple sclerosis. Nursing Times 101(2):48–52, 2005. Medline abstracts
  96. Calabresi P: Diagnosis and management of multiple sclerosis. Am Fam Physician 70(10):1–14, 2004.
  97. Lee AG, Berlie CL: Multiple sclerosis, eMedicine updated September 22, 2010. Available at: www.emedicine.com/oph/topic179.htm. Accessed March 3, 2011.
  98. Ramchandren S: The immunopathogenesis of Guillain-Barré syndrome. Clin Adv Hematol Oncol 8(3):203–206, 2010. Medline abstracts
  99. Lehmann HC: Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis 10(9):643–651, 2010. Medline abstracts
  100. Farrugia ME, Vincent A: Autoimmune mediated neuromuscular junction defects. Curr Opin Neurol 23(5):489–495, 2010. Medline abstracts
  101. Cantor F: Central and peripheral fatigue: exemplified by multiple sclerosis and myasthenia gravis. PM R 2(5):399–405, 2010. Medline abstracts
  102. Angelini C: Diagnosis and management of autoimmune myasthenia gravis. Clin Drug Investig 31(1):1–14, 2011. Medline abstracts
  103. Scherer K, Bedlack RS, Simel L: Does this patient have myasthenia gravis? JAMA 293(15):1906–1914, 2005. Medline abstracts
  104. Magee DJ: Orthopedic physical assessment, ed 5, Philadelphia, 2008, WB Saunders.
  105. Janssen RS, Onorato IM: Advancing HIV prevention: new strategies for a changing epidemic—United States, 2003. MMWR 52(15):329–332, 18, 2003. Medline abstracts
  106. Porter K, Babiker A, Bhaskaran K: Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362(9392):1267–1274, 2003. Medline abstracts
  107. Kubis KC, Danesh-Meyer HV, Savino PJ, et al: The ice test versus the rest test in myasthenia gravis. Ophthalmology 107(11):1995–1998, 2000. Medline abstracts